A 77-year-old woman without traditional risk factors for coronary artery disease (CAD) underwent coronary CTangiography for evaluation of palpitations after negative Holter monitoring and non-diagnostic ECG exercise stress test. Coronary artery calcium score was reported zero; 1 day later, she was admitted with anteriorwall ST elevation myocardial infarction. Acute left anterior descending artery thrombus was treated with mechanical thrombectomy and Percutaneous Coronary Intervention (PCI). Interestingly, the coronary arteries were angiographically normal. During hospitalisation, paroxysmal atrial fibrillation was noted followed by initiation of anticoagulation. Echocardiogram did not show thrombus or atrial shunt. Cardioversion with Sotalol was successful. Myocardial infraction was most likely cardioembolic secondary to paroxysmal atrial fibrillation-consistent with longstanding history of palpitations. Accounting for 3% of acute coronary syndromes, coronary embolism is treated with therapeutic anticoagulation for at least 3 months irrespective of cause and carries a higher risk of adverse cardiovascular events.
Summary
A 77-year-old woman without traditional risk factors for coronary artery disease (CAD) underwent coronary CTangiography for evaluation of palpitations after negative Holter monitoring and non-diagnostic ECG exercise stress test. Coronary artery calcium score was reported zero; 1 day later, she was admitted with anteriorwall ST elevation myocardial infarction. Acute left anterior descending artery thrombus was treated with mechanical thrombectomy and Percutaneous Coronary Intervention (PCI). Interestingly, the coronary arteries were angiographically normal. During hospitalisation, paroxysmal atrial fibrillation was noted followed by initiation of anticoagulation. Echocardiogram did not show thrombus or atrial shunt. Cardioversion with Sotalol was successful. Myocardial infraction was most likely cardioembolic secondary to paroxysmal atrial fibrillation-consistent with longstanding history of palpitations. Accounting for 3% of acute coronary syndromes, coronary embolism is treated with therapeutic anticoagulation for at least 3 months irrespective of cause and carries a higher risk of adverse cardiovascular events.
BaCkground
Estimated 3% of acute coronary syndromes (ACS) are caused by coronary embolism (CE). In patients with ACS without significant underlying coronary artery disease (CAD), embolic aetiology should be considered. Diagnosis of CE may be difficult in patients with paroxysmal atrial fibrillation, as the rhythm may be normal at presentation. Identification of CE subgroup of patients with ACS is important because of increased risk for major adverse cardiac outcomes and importance of systemic anticoagulation in prevention of future embolic events.
CaSe preSenTaTion
A 77-year-old non-smoker woman presented with sudden onset substernal chest pain radiating to the left arm. ECG showed anterior wall ST-elevation myocardial infarction (STEMI). Haemodynamically stable, emergent cardiac catheterisation revealed a 100% acute occlusion of the proximal left anterior descending artery (LAD, figure 1A ). Left main, circumflex and right coronary arteries were normal (0% stenosis reported); no circumflex-LAD or right coronary artery (RCA)-LAD collaterals were noted. Mechanical thrombectomy was performed followed by the placement of two stents in the proximal LAD. Guideline-directed post-STEMI medical therapy was initiated: aspirin, clopidogrel, beta-adrenergic antagonist, statin and ACE inhibitor.
Few weeks prior to her presentation with STEMI, the patient was seen in outpatient cardiology office for daily symptoms of palpitations and progressive exertional dyspnoea. According to the patient, her heartbeat has 'felt irregular' for several years. No prior history of hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation or cardiovascular disease was reported. At the office visit, 12-lead ECG was sinus rhythm with premature ventricular complexes (PVCs). 24 hours Holter monitor was notable for sinus rhythm with premature atrial contractions (2.1% of beats) and PVCs (1.2% of beats). The patient then underwent an ECG stress test with non-diagnostic ST and T wave changes.
Given the non-diagnostic stress test and atypical symptoms, 1 day prior to her presentation with STEMI, a coronary CT angiogram was performed which revealed a coronary artery calcium (CAC) score of zero and no CAD whatsoever. unusual presentation of more common disease/injury patient denied miscarriages or arterial/venous thrombosis. Likewise, no history of atrial septal defect, endocarditis or recent/ remote cardiac intervention was reported. Transthoracic echocardiogram was unrevealing for an intracardiac shunt, thrombus or mass. Despite extensive discussion and explanation of the diagnostic and therapeutic benefit, the patient declined transoesophageal echocardiography. Extended ambulatory rhythm monitoring was planned but on the second day of hospitalisation, paroxysmal atrial fibrillation was recorded on telemetry (figure 2).
TreaTmenT
Systemic oral anticoagulation was initiated (Apixaban 5 mg two times per day) followed by successful pharmacologic cardioversion with Sotalol. Dual antiplatelet (aspirin and clopidogrel) and post-STEMI guideline-directed medical therapy were continued, including high intensity statin and ACE inhibitor, but metoprolol was replaced by Sotalol.
ouTCome and follow-up
The patient was discharged after unremarkable 72 hours monitoring for QTc prolongation post-initiation of Sotalol. Triple therapy with aspirin, clopidogrel and apixaban was continued at discharge with the intent to discontinue aspirin after 6 weeks to minimise bleeding risk. No chest pain, exertional dyspnoea or heart failure symptoms were reported at 1 week follow-up. The patient's ECG showed normal sinus rhythm with resolving ST-elevations. Ejection fraction was preserved on repeat transthoracic ECHO. Monthly appointments are scheduled for close monitoring and observation for bleeding on long-term anticoagulation (CHA2DS2VASc score=5) and clopidogrel.
diSCuSSion
Causes of CE are broadly divided into three categories: direct, paradoxical and iatrogenic. 1 In causes classified as direct, the embolus originates from a thrombus in the left atrium and ventricle, mitral and aortic valves, pulmonary veins or proximal coronary artery-with paroxysmal or persistent atrial fibrillation being the most common cause (73%). 2 Other direct aetiologies of CE due to the left-sided thrombus include endocarditis and post-myocardial infraction left ventricular thrombus. 1 Paradoxical CE may also be secondary to venous thrombi entering the systemic circulation through an atrial septal defect, patent foramen ovale or pulmonary arteriovenous malformation. 1 When compared with the cerebral and systemic circulation, the coronary arterial vasculature is relatively protected from emboli because of difference in calibre of the aorta and main coronary arteries, the acute angle at which the coronaries originate from the aorta, and the fast flow across the coronary ostia. 1 Consequently, CE is a rare cause of ACS overall (2.9%) and STEMI (4.3%). 2 3 Clinical presentation of acute myocardial infarction due to CE is indistinguishable from atherosclerotic myocardial infarction. 1 Consequently, the initial ACS management is the same, regardless of the aetiology. However, recognition of CE, in addition to specific medical management, is important because of the need for closer monitoring in this subpopulation and increased risk of cardiac death as compared with the patients with atherosclerotic myocardial infarction. 3 Patients with CE myocardial infarction suffer from significantly increased 5-year risk of adverse cardiac and cerebrovascular events, which may be as high as 27%. 2 Age greater than 60 years, female gender, reduced left ventricular ejection fraction and atrial fibrillation are independent risk factors for major adverse cardiovascular events in patients with non-atherosclerotic myocardial infarction, 4 emphasising the importance of recognising CE and associated prognostic factors.
CE diagnosis may be suspected on retrospective evaluation of coronary angiogram when the occlusive thrombus burden is disproportionate to the degree of atherosclerosis, no or minimal atherosclerosis in other coronary territories, or there is evidence of concomitant systemic embolisation in other arterial beds, for example, cerebral, mesenteric, retinal or in extremities. 2 Compared with those patients with atherosclerotic CAD, patients with CE are less likely to have traditional risk factors-hypertension, dyslipidemia, smoking and diabetes. 5 However, it may reflect a selection bias, as more thorough search for embolic source is performed in patients with ACS without significant risk factors for systemic atherosclerosis. Anticoagulation is the treatment of choice for all patients with CE, and thrombophilia testing is not routinely indicated. 1 However, decision for testing needs to be individualised, for instance to determine duration of treatment in patients with unexplained venous thromboembolism and/or who are at higher risk for bleeding.
Major CE diagnostic criteria (suggested by Shibata et al 2 ) include (1) angiographic findings of coronary vessel occlusion without atherosclerosis; (2) concomitant involvement of multiple coronary territories and/or distal systemic embolism; (3) histologic evidence of venous thrombus and (4) echocardiographic/ CT/MRI evidence of intracardiac thrombus. Minor criteria include (1) <25% stenosis of non-culprit coronary vessels, (2) known atrial fibrillation and (3) risk factor for embolism (eg, patent foramen ovale, atrial septal defect, dilated cardiomyopathy, prosthetic valve, etc.). Our patient met one major criterion (angiographic evidence of large thrombus without significant underlying atherosclerosis, figure 1B) and two minor criteria unusual presentation of more common disease/injury (atrial fibrillation and <25% stenosis in non-culprit vessels) qualifying as definite CE. 2 There was no significant coronary atherosclerosis by invasive angiogram in the acute setting. Moreover, a coronary CTA performed just 1 day prior to the STEMI presentation did not reveal any evidence for atherosclerotic disease whatsoever. False-negative results of CT coronary angiography do occur with reported negative predictive values of 80%-90%. 6 However, these false-negative results typically occur in patients with atherosclerotic disease in whom a particular intracoronary lesion is 'undercalled' by the reader. In the case presented, the CAC score of 0 and finding of no non-calcified plaque make a false-negative CT result very unlikely. Finally, in some patients, myocardial infarction may cause atrial fibrillation. 7 But our patient had longstanding history of palpitations which, in retrospect, were probably due to undiagnosed paroxysmal atrial fibrillation. In suspected embolic infarct, post-thrombectomy intravascular ultrasound would have been useful in ruling out dissection or eroded plaque and, in the presence of normal vessel morphology, would have confirmed the diagnosis of embolism. 8 In confirmed embolic myocardial infarction, it would have obviated the need for triple antithrombotic therapy (dual antiplatelet and anticoagulation).
The chronology of events in the presented case serves as a reminder of the clinical characteristics associated with CE, its diagnostic evaluation and treatment to reduce risk of recurrence. Although there are no formal guidelines for management of CE, workup should include extended cardiac rhythm monitoring for detection of paroxysmal or persistent atrial fibrillation (the most common cause of CE) and transoesophageal echocardiography for detection of left atrial thrombus and right-to-left shunt. In retrospect, delayed enhancement cardiac MRI could have been offered as an alternative to transoesophageal echocardiography for left atrial thrombus detection. 9 The recommended treatment for CE is systemic anticoagulation. The duration of anticoagulation in CE due to paradoxical right-to-left embolism depends on the underlying thrombosis aetiology and risk-profile, with treatment duration of 3 months if risk factors are transient, or longer if persistent. 1 As in the presented patient, if atrial fibrillation is detected (CHA2DS-2VASc assigned to a minimum of two in men and three in women with CE), long-term anticoagulation is indicated. Additional complexity of patient care and increased bleeding risk due to dual antiplatelet therapy and systemic anticoagulation should be considered as well. In patients with increased bleeding risk on dual antiplatelet therapy who require systemic anticoagulation, aspirin may be stopped 4 weeks after the acute event with acceptable long-term outcomes. 7 Thrombectomy and longterm anticoagulation are adequate therapy for CE secondary to atrial fibrillation. The role of left atrial appendage closure for prevention of the CE events in patients with atrial fibrillation is currently unclear. This case highlights the benefit of evaluating suspected CE with intravascular ultrasound or optical coherence tomography post-thrombectomy to avoid unnecessary percutaneous coronary intervention and bleeding risk associated with triple antithrombotic therapy. learning points ► Coronary embolism (CE) is an under-recognised cause of acute coronary syndrome associated with worse cardiac and cerebrovascular outcomes compared with atherosclerotic heart disease. ► Atrial fibrillation is the most common cause of CE. Longterm rhythm monitoring for detection of atrial fibrillation is indicated. ► Thrombophilia testing is not routinely indicated in CE except for unexplained venous thrombosis. ► Increased bleeding risk due to dual antiplatelet therapy and systemic anticoagulation should be considered. Evaluation of suspected CE with post-thrombectomy intravascular ultrasound may prevent unnecessary percutaneous coronary intervention and bleeding risk associated with triple antithrombotic therapy.
Contributors MHSS and MAS drafted the manuscript. MT and LS helped with editing and literature review.
funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
